- Also known as
- Wolverine blend · Wolverine peptide · BPC 157 TB 500 · BPC-157/TB-500 · BPC 157 and TB 500 blend
- Class
- Two-peptide research blend pairing a gastric pentadecapeptide with a thymosin beta-4 related peptide
- Form
- Lyophilised powder supplied in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is Wolverine?
Wolverine blend (BPC-157 + TB-500) comes as a single vial carrying BPC-157 5 mg and TB-500 5 mg together in one lyophilised powder. The literature studies the two apart from each other, and the references gathered on this page are those separate studies. The published research spans rat, human and mouse work. It has reached people in 4 studies, none of them controlled, so those outcomes cannot be separated from everything else that shifted alongside. We stock it as a lyophilised powder in 10 mg vials, for laboratory work only. It holds no medicinal authorization and is not for use in any living subject.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Lee E et al.2021 · Altern Ther Health Med · PMID 34324435 | Human, retrospective chart review with phone survey (n=16, knee pain); 4 of the 16 received BPC-157 and TB4 | Intra-articular BPC-157 alone (n=12) or BPC-157 and TB4 as two peptide injections (n=4); amounts not stated in the abstract | Most patients surveyed 6 months to 1 year after the injection | Eleven of 12 given BPC-157 alone reported significant improvement in knee pain. Of the 4 given both peptides, 75% reported significant improvement and 25% had no relief. No specific tools were used to measure function or quality of life, and there was no control group. |
| Lee E et al.2024 · Altern Ther Health Med · PMID 39325560 | Human, uncontrolled pilot study (n=12 women with interstitial cystitis), private clinic | 10 mg total, given by injection around the inflamed area of the bladder during cystoscopy | Single procedure; follow-up period not stated in the abstract | Ten of 12 patients reported complete resolution of symptoms and 2 of 12 rated their success at 80%. No adverse events were reported. The study had no control group. |
| Lee E et al.2025 · Altern Ther Health Med · PMID 40131143 | Human, safety pilot (n=2 adults), private clinic | 10 mg in 250 cc normal saline over one hour on day 1, then 20 mg on day 2 (intravenous) | 3 days | The infusions produced no measurable effects on the tested heart, liver, kidney and thyroid biomarkers or blood glucose, and no side effects were reported. |
| Sun YS et al.2025 · World J Gastroenterol · PMID 41278163 | Human colonic mucus (IBS patients); mouse and rat (Tβ4-deficient) models | Not stated in the abstract | Not stated in the abstract | Tβ4 treatment of mice reduced tight junction proteins in the gut lining, and Tβ4 released from mast cells under stress disrupted the intestinal epithelial barrier. |
| Perovic D et al.2019 · J Orthop Surg Res · PMID 31266512 | Rat, spinal cord compression injury model | 200 or 2 μg/kg, one intraperitoneal injection 10 min after injury | Assessed at 1, 4, 7, 15, 30, 90, 180 and 360 days | Injured rats given BPC-157 showed better tail motor function, no autotomy and resolved spasticity by day 15, with less axon loss, oedema and motoneuron loss on microscopy. |
| Maar K et al.2025 · Int J Mol Sci · PMID 40362372 | Mouse, permanent coronary ligation (heart attack) model; human cardiac cells | Systemic TB4 injection; amount not stated in the abstract | Not stated in the abstract | TB4 raised miR139-5p expression and modulated ROCK1 protein levels in mouse hearts and human cardiac cells, and may reverse or inhibit fibroblast-to-myofibroblast transformation. |
| Li H et al.2018 · J Gene Med · PMID 29972714 | Mouse, CCl4-induced liver fibrosis model (gene delivery, not peptide); liver cells in vitro | Intraperitoneal adeno-associated virus encoding Tβ4 (AAV-Tβ4); amount not stated in the abstract | Not stated in the abstract | AAV-Tβ4 pre-treatment significantly reduced liver injury, collagen deposition, stellate cell activation and pro-fibrotic cytokines. |
| Li Y et al.2025 · J Allergy Clin Immunol · PMID 39978686 | Mouse, house dust mite allergic asthma model (BDCA2-DTR mice); cell experiments | Tβ4 supplementation; amount not stated in the abstract | Not stated in the abstract | Tβ4 supplementation reversed the worsened asthma phenotype in mice depleted of plasmacytoid dendritic cells, and Tβ4 inhibited IL-4/IL-13-induced JAK1/STAT6 signalling in macrophages. |
What these studies don't show: The human work here has no controls: pilot studies, case reports and retrospective reviews. Lacking a control group, none can show the compound caused what was observed. Neither the length nor the size of these studies will carry a safety conclusion. Knowing the vial contains what the label claims is a separate thing from knowing the compound does anything at all.
Every study links to its PubMed record. See all Wolverine studies in the research library →
Wolverine price in Canada: 10mg vial
Buy BPC 157 TB 500 (Wolverine) in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $71.00 | $7.10/mg |
Starter kit
Is Wolverine available in Canada?
No Wolverine blend (BPC-157 + TB-500) product carries a Drug Identification Number in Canada. No regulator here has examined its safety, efficacy or quality. Kept by Borealis Peptides for in-vitro research, it is supplied for use in no living subject. How Health Canada treats research peptides →
Side effects reported in studies
Where a cited study said anything about tolerability, its exact wording is reproduced below. Human work on this scale cannot build a safety profile.
Wolverine FAQ
What is Wolverine blend (BPC-157 + TB-500)?
Both suppliers and the literature describe Wolverine blend (BPC-157 + TB-500) as a two-peptide research blend: a gastric pentadecapeptide alongside a thymosin beta-4 related peptide. The published research spans rat, human and mouse work. Borealis Peptides offers it as a lyophilised powder in 10 mg vials for in-vitro laboratory research. It is no drug, nor is it supplied for use in a person or an animal. Each reference here appears alongside the model it ran in and the result as it was published.
Where can I buy Wolverine blend (BPC-157 + TB-500) in Canada?
Borealis Peptides sends Wolverine blend (BPC-157 + TB-500) out of Canadian stock to research and business addresses within Canada. It comes in 10 mg vials. HPLC tests every batch, and the certificate names the batch in your vial. Orders are taken for laboratory research only.
Is Wolverine blend (BPC-157 + TB-500) legal in Canada?
No Wolverine blend (BPC-157 + TB-500) product carries a Drug Identification Number in Canada. No regulator here has examined its safety, efficacy or quality. For Borealis Peptides this is in-vitro research material only, never supplied for use in a living subject. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we take it to describe what the material is supplied for, never a licence to use it.
How much Wolverine blend (BPC-157 + TB-500) should I use?
There is none to give. Nothing on this site amounts to a protocol, a schedule or a reconstitution volume. The quantities in the cited studies belong to those studies and the models they ran in, and they are listed so the evidence can be weighed instead of taken on trust.
What human evidence is there for Wolverine blend (BPC-157 + TB-500)?
Human work exists, but none of it is controlled. 4 studies involved people, in the form of pilots, case reports or retrospective reviews. Absent a control group, none can prove the compound caused what was seen, and the page states as much next to the table.
Does Wolverine blend (BPC-157 + TB-500) need refrigeration?
Keep sealed vials at −20 °C, dry and shielded from light. Solutions are kept at 2–8 °C. The lyophilised powder withstands ambient temperature in transit, so it ships without ice and goes into the fridge on arrival. Keeping it dark and at a steady temperature counts for more than how quickly it reached you.
How is the purity of Wolverine blend (BPC-157 + TB-500) confirmed?
HPLC tests each batch before it is sold, and the certificate points to the batch in your vial rather than to the product at large. Filing that batch number with your records is what lets an observation be reproduced later. Certificates are available on request.
How does Wolverine blend (BPC-157 + TB-500) compare with BPC-157 and TB-500?
Each carries its own published record, and comparing them comes down to reading both. BPC-157 and TB-500 have 7 cited studies and 7 cited studies on their page against 8 here. What sets them apart is the published work, which both pages lay out in full.
Why is Wolverine blend (BPC-157 + TB-500) named in a Health Canada advisory?
Because it was one of the peptides seized from sellers putting unauthorized injectable products online. The advisory addresses material sold for people to inject without authorization. Borealis Peptides deals only in research material for in-vitro work and puts up nothing for injection or for any use in a person, placing it on the safe side of the line the advisory draws.







